Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
523 stopped studies mapped to Lymphoid Leukemia and descendants · 86% state a reason
Over the 523 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | Phase 1 | terminated | Jul 26, 2018 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT02309515 | Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic… | Phase 2 | terminated | Dec 5, 2014 | Mayo Clinic | Slow Accrual | Enrollment / accrual |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic… | Phase 1 | terminated | Jul 18, 2012 | Barbara Ann Karmanos Cancer Institute | Study terminated due to slow accrual. | Enrollment / accrual |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT02538614 | Study of Idelalisib in Combination With BI 836826 in Participants With Chronic… | Phase 1 | terminated | Sep 2, 2015 | Gilead Sciences | not stated | Not stated |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib… | Phase 2 | terminated | Feb 27, 2013 | Gilead Sciences | Sponsor's decision to discontinue development of entospletinib. | Sponsor / business decision |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R… | Phase 1 | withdrawn | Sep 19, 2019 | Second Affiliated Hospital of Xi'an Jiaotong University | Production plan adjustment | Other (stated, no rule matched) |
| NCT01483690 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | Phase 1 / Phase 2 | terminated | Dec 1, 2011 | Therapeutic Advances in Childhood Leukemia Consortium | Toxicity | Safety / toxicity |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | Phase 1 | terminated | Apr 25, 2016 | Washington University School of Medicine | Toxicity. Only enrolled patients in phase I portion of trial. | Safety / toxicity |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | Phase 1 / Phase 2 | terminated | Jan 31, 2017 | Sunesis Pharmaceuticals | Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib… | Sponsor / business decision |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | Phase 1 / Phase 2 | terminated | Sep 22, 2009 | Therapeutic Advances in Childhood Leukemia Consortium | Slow accrual rate | Enrollment / accrual |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT03888534 | Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute… | Phase 1 | withdrawn | Mar 25, 2019 | Millennium Pharmaceuticals, Inc. | Business decision (no safety or efficacy concerns) | Safety / toxicity |
| NCT01658007 | Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute…(SIR-MO-1101) | Early Phase 1 | terminated | Aug 6, 2012 | Children's Hospital Medical Center, Cincinnati | Slow Accrual | Enrollment / accrual |
| NCT03985215 | The Value of Follow-Up After Childhood Acute Lymphoblastic Leukaemia in Denmark - Family… | — | withdrawn | Jun 13, 2019 | University of Aarhus | Overlapping with another danish questionnaire study | Other (stated, no rule matched) |
| NCT03515200 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic… | Phase 1 | terminated | May 3, 2018 | St. Jude Children's Research Hospital | Due to departure of PI from St. Jude | Other (stated, no rule matched) |
| NCT02767934 | Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic… | Phase 2 | terminated | May 11, 2016 | University of Washington | Terminated due to lack of efficacy | Efficacy / futility |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After… | Phase 1 | terminated | May 7, 2008 | University of Pennsylvania | Insufficient funds | Funding |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood… | Phase 1 | withdrawn | Jan 16, 2019 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT00983528 | Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | terminated | Sep 24, 2009 | University of California, San Diego | Support withdrawn due to slow accrual | Enrollment / accrual |
| NCT01551043 | Allo CART-19 Protocol | Phase 1 | terminated | Mar 12, 2012 | University of Pennsylvania | Administrative Reasons | Other (stated, no rule matched) |
| NCT03628053 | Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory…(OBERON) | Phase 3 | withdrawn | Aug 14, 2018 | Novartis Pharmaceuticals | Novartis is no longer pursuing this study because of planned investigation of novel CAR-T therapies… | Other (stated, no rule matched) |
| NCT01003769 | Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Oct 29, 2009 | Mayo Clinic | Lack of funding | Funding |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory… | Phase 2 | terminated | Feb 21, 2013 | Gilead Sciences | Study was terminated due to safety measures. | Safety / toxicity |
| NCT02535364 | Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic…(ROCKET) | Phase 2 | terminated | Aug 28, 2015 | Juno Therapeutics, a Subsidiary of Celgene | Safety reasons | Safety / toxicity |
| NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | — | terminated | Feb 19, 2018 | Juno Therapeutics, a Subsidiary of Celgene | Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects… | Enrollment / accrual |
| NCT02349178 | Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT | Phase 2 | terminated | Jan 28, 2015 | Medical College of Wisconsin | Low accrual | Enrollment / accrual |
| NCT02588092 | Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid… | Phase 1 | terminated | Oct 27, 2015 | ADC Therapeutics S.A. | Slow enrollment | Enrollment / accrual |
| NCT01629511 | Allogeneic Stem Cell Transplant for CLL | Phase 1 / Phase 2 | terminated | Jun 27, 2012 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT02819804 | Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia… | Phase 1 | terminated | Jun 30, 2016 | Northwestern University | Due to funding and accrual issues | Enrollment / accrual |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Phase 1 | withdrawn | Aug 2, 2019 | Dana-Farber Cancer Institute | Business development reasons. | Sponsor / business decision |
| NCT00899431 | Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | May 12, 2009 | M.D. Anderson Cancer Center | Terminated per PI's request at the time of continuing review | Other (stated, no rule matched) |
| NCT02404220 | Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With… | Phase 1 / Phase 2 | terminated | Mar 31, 2015 | Gilead Sciences | not stated | Not stated |
| NCT02435550 | iCare for Cancer Patients | N/A | terminated | May 6, 2015 | University of Florida | Halted due to funding issues. | Funding |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells… | Phase 1 | terminated | Sep 4, 2014 | National Heart, Lung, and Blood Institute (NHLBI) | not stated | Not stated |
| NCT02557516 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or… | Phase 1 / Phase 2 | terminated | Sep 23, 2015 | Innate Pharma | Sponsor decision | Sponsor / business decision |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | Phase 1 | terminated | Aug 20, 2001 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01754870 | Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by… | Phase 2 | withdrawn | Dec 21, 2012 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT01747499 | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | Phase 1 / Phase 2 | terminated | Dec 11, 2012 | Washington University School of Medicine | Enrolling 8 more patients would be statistically unlikely that the primary endpoint would be… | Enrollment / accrual |
| NCT02784834 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | Phase 1 | terminated | May 27, 2016 | Michael Choi | lack of funding | Funding |
| NCT01408160 | Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Aug 3, 2011 | Albert Einstein College of Medicine | not stated | Not stated |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | Phase 2 | terminated | Jan 13, 2006 | Masonic Cancer Center, University of Minnesota | Drug was not available. | Other (stated, no rule matched) |
| NCT02614508 | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Nov 25, 2015 | Emory University | not stated | Not stated |
| NCT01090414 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101;… | Phase 1 / Phase 2 | terminated | Mar 22, 2010 | Gilead Sciences | not stated | Not stated |
| NCT01539291 | Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who… | Phase 3 | terminated | Feb 27, 2012 | Gilead Sciences | not stated | Not stated |
| NCT00949988 | A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia(BMS-CA180105) | Phase 1 / Phase 2 | terminated | Jul 31, 2009 | University of California, San Diego | Three subjects were enrolled and all three subjects withdrew. | Enrollment / accrual |
| NCT01659021 | Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated… | Phase 3 | terminated | Aug 7, 2012 | Gilead Sciences | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 22, 2021source: clinicaltrials